Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases - Slideshow Markets 19 d ago
Wells Fargo cuts Alumis stock price target on SLE trial results Markets 21 d ago 3 sources also on SLE WFC
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript Markets 23 d ago